secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2025-09-19T23:59:59+00:00
Accession:  0001193125-25-209259
Event type: leadership
Sentiment:  negative
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025
---------------------------------------------------------------------

- Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.
- Company determined termination without 'Cause' under Change in Control and Severance Benefit Plan.
- No successor or interim CSO announced; departure of named executive officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312525209259/0001193125-25-209259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312525209259/janx-20250918.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-209259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer